Tuesday, April 17, 2012

13th Annual Business of Biosimilars and Generic Drugs agenda now available

After years of waiting, in which your business came ever closer to the “patent cliff,” the FDA has released its long-awaited user fee structure and draft guidelines for the development and regulatory approval of biosimilars in the United States.

The 13th Annual Business of Biosimilars and Generic Drugs event is designed to help you focus on the most significant new points in these guidelines and further accelerate what indeed promises to be a significantly abbreviated path to approval for your follow-on biologics.  It will take place September 10-12, 2012 in Boston, MA.

No other event focuses so sharply on eliminating the obstacles you face in the commercialization of your next biosimilar candidate. This year we are particularly proud to feature time-sensitive updates on the biggest news now facing the industry!

What is featured in this year’s Business of Biosimilars and Generic Drugs event?
  • - FDA Regulatory Updates
  • - Strategic Partnerships
  • - Learning the right market lessons from generic drugs

Download the complete 2012 program here.

Share this article with your social network, just click below to share now!

No comments :

Post a Comment